Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway.

ABSTRACT:

Aim

Regorafenib is an oral small-molecule multi kinase inhibitor. Recently, several clinical trials have revealed that regorafenib has an anti-tumor activity in gastric cancer. However, only part of patients benefit from regorafenib, and the mechanisms of regorafenib's anti-tumor effect need further demonstrating. In this study, we would assess the potential anti-tumor effects and the underlying mechanisms of regorafenib in gastric cancer cells, and explore novel biomarkers for patients selecting of regorafenib.

Methods

The anti-tumor effects of regorafenib on gastric cancer cells were analyzed via cell proliferation and invasion. The underlying mechanisms were demonstrated using molecular biology techniques.

Results

We found that regorafenib inhibited cell proliferat

SUBMITTER: Lin XL 

PROVIDER: S-EPMC5425213 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature